Extracellular Matrix Markers and Methods for Their Study (Review)

Tush, E.V.; Eliseeva, T.I.; Khaletskaya, O.V.; Krasilnikova, S.V.; Ovsyannikov, D.Yu.; Потемина, Т. Е.; Ignatov, Stanislav K.

doi:10.17691/stm2019.11.2.20

Cited by 6 publications

(1 citation statement)

References 38 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is associated with atopic syndrome and is characterized by a good response to therapy with topical glucocorticoids [ 12 , 18 , 19 ]. Th2-dependent allergic inflammation can trigger remodeling of the NM and contribute to hypertrophic and hyperplastic changes, including polyposis [ 20 – 23 ]. Patients with a Th2-dependent inflammatory endotype have the most severe and refractory course of the disease [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

Krasilnikova¹,

Tush²,

Frolov³

et al. 2020

Sovrem Tehnol Med

Self Cite

View full text Add to dashboard Cite

The involvement of periostin in Th2-dependent allergic inflammation has been documented. However, the significance of periostin as a biomarker of local allergic inflammation in the nasal mucosa (NM) of patients with atopic bronchial asthma (BA) and allergic rhinitis (AR) is yet to be determined. The aim of the study was to determine the presence of periostin and evaluate its role as a non-invasive marker of allergic inflammation in the nasal secretions of children with atopic BA and AR. Materials and Methods. In 43 patients aged 4–17 years with atopic BA and AR, the NM was examined using nasal video-endoscopy and (if indicated) computed tomography; the amount of periostin in the nasal secretion was determined by the enzyme immunoassay. Results. Exacerbation of AR was accompanied by a statistically significant increase in the level of periostin in the nasal secretion: up to 0.84 [0.06; 48.79] ng/mg, whereas in remission, that was 0.13 [0.00; 0.36] ng/mg; p=0.04. This value increased progressively as the severity of AR increased from 0.16 [0.00; 0.36] ng/mg in the mild course to 0.20 [0.00; 9.03] ng/mg in AR of moderate severity, and to 10.70 [0.56; 769.20] ng/mg in most severe cases; p=0.048. Hypertrophy or polyposis of the nasal and/or paranasal mucosa was detected in 34.9% (15/43) of the examined patients. The concentration of periostin in the nasal secretion was lower in children without NM hypertrophy: 0.18 [0.001; 4.30] ng/mg vs 0.78 [0.13; 162.10] ng/mg in patients with NM hypertrophy; the differences were close to statistically significant: p=0.051. The level of nasal periostin depended on the clinical form of hypertrophy in the sinonasal mucosa, reaching 0.17 [0.00; 0.32] ng/mg in children with polyposis hyperplasia of NM and 21.6 [10.70; 1516.80] ng/mg — with hypertrophy of the NM in the medial surface of the concha; p=0.02. Conclusion. Exacerbation and increased severity of AR in patients with atopic BA are accompanied by an increased level of periostin in the nasal secretion. This allows us to consider the level of nasal periostin as a biomarker of local allergic inflammation in the NM of patients with atopic BA combined with AR. Hypertrophic changes in the sinonasal mucosa are generally accompanied by an increased level of nasal periostin; specifically, this level significantly depends on the clinical form of mucous membrane hypertrophy and requires additional studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

Krasilnikova¹,

Tush²,

Frolov³

et al. 2020

Sovrem Tehnol Med

Self Cite

View full text Add to dashboard Cite

show abstract

Disorders of the Biochemical Composition of the Periodontium in Rats with Periodontitis and Chronic Pain Syndrome

et al. 2022

View full text Add to dashboard Cite

Joint involvement in patients with acromegaly: potential markers for early diagnosis

Perepelova,

Lutsenko,

Utkina

et al. 2024

Obes. metabol.

View full text Add to dashboard Cite

Acromegaly is a rare neuroendocrine disease caused by excessive production of growth hormone (GH), which acts as a trigger for cartilage tissue destruction leading to joint damage.Patients with acromegaly, especially in the active stage, often complain of joint pain in various locations. Joint pain can be one of the first symptoms of the disease, the intensity of which worsens without proper treatment. Increased production of GH leads to configuration changes in the joints, which in turn trigger destructive processes typical of degenerative diseases such as osteoarthritis. Despite successful treatment of acromegaly, joint-related issues can persist and significantly worsen the quality of life for patients. In this regard, the search for potential markers of early joint involvement in acromegaly is relevant for use in predicting the severity of arthropathy progression and monitoring this cohort of patients.This review provides a general overview of the effects of growth hormone on cartilage tissue, the characteristics of musculoskeletal pathology in patients with acromegaly and possible markers associated with early joint damage.

show abstract

Extracellular Matrix Markers and Methods for Their Study (Review)

Cited by 6 publications

References 38 publications

Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

Disorders of the Biochemical Composition of the Periodontium in Rats with Periodontitis and Chronic Pain Syndrome

Joint involvement in patients with acromegaly: potential markers for early diagnosis

Contact Info

Product

Resources

About